Background: Allergen-specific immunotherapy (SIT) is currently the only curative treatment for allergy but the treatment needs to be improved. We hypothesize that covalent coupling of immunomodulating vitamin D3 to the major cat allergen Fel d 1 can enhance the beneficial effects of SIT to cat allergy. Methods: We treated mice sensitized to Fel d 1 with subcutaneous injections of two doses of recombinant Fel d 1 coupled to 1α,25-dihydroxyvitamin D3 (rFel d 1:VD3) and compared to treatment with the same doses of rFel d 1 in a mouse model for cat allergy. Airway hyperresponsiveness (AHR), cytokines and cells in bronchoalveolar lavage (BAL), in vitro activation of splenocytes to rFel d 1, and Fel d 1-specific immunoglobulins were evaluated. Results: Treatment with both doses of rFel d 1:VD3 decreased AHR, cellular influx and Th2 cytokines in BAL compared to untreated mice. High- and low-dose rFel d 1 treatment also decreased AHR and BAL Th2 cytokines, with less decrease for the low-dose treatment. Importantly, the total number of cells and eosinophils in BAL was markedly reduced at both high- and low-dose rFel d 1:VD3 compared to treatment with rFel d 1 alone. Finally, treatment with both rFel d 1 and rFel d 1:VD3 induced Fel d 1-specific serum IgG. Conclusion: Our results indicate a beneficial therapeutic effect of rFel d 1:VD3 on airway inflammation, AHR and rFel d 1-specific immune responses and thus suggest that this novel immunomodulatory candidate may improve both the efficacy and safety of SIT.

Keywords:
Allergen-specific immunotherapy, Cat allergy, Fel d 1, Mouse model, Vitamin D3
1.
Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558–562.
2.
Nanda A, O’Connor M, Anand M, Dreskin SC, Zhang L, Hines B, Lane D, Wheat W, Routes JM, Sawyer R, Rosenwasser LJ, Nelson HS: Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004;114:1339–1344.
3.
van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944–2952.
4.
Wachholz PA, Soni NK, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915–922.
5.
Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187–4194.
6.
Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O: Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007–1015.
7.
Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205–1214.
8.
Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255–1261.
9.
Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252–3259.
10.
Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707–713.
11.
Windom HH, Lockey RF: An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008;8:571–576.
12.
Terada T, Zhang K, Belperio J, Londhe V, Saxon A: A chimeric human-cat Fcgamma-Fel d 1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d 1, the major cat allergen. Clin Immunol 2006;120:45–56.
13.
Hulse KE, Reefer AJ, Engelhard VH, Satinover SM, Patrie JT, Chapman MD, Woodfolk JA: Targeting Fel d 1 to FcγRI induces a novel variation of the T(H)2 response in subjects with cat allergy. J Allergy Clin Immunol 2008;121:756–762, e754.
14.
Martinez-Gomez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, Crameri R, Kundig TM: Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009;64:172–178.
15.
Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, Saudan P, Bachmann MF: Displaying Fel d 1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009;206:1941–1955.
16.
Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002;109:455–462.
17.
Mo JH, Park SW, Rhee CS, Takabayashi K, Lee SS, Quan SH, Kim IS, Min IY, Raz E, Lee CH: Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis. Am J Rhinol 2006;20:212–218.
18.
Neimert-Andersson T, Thunberg S, Swedin L, Wiedermann U, Jacobsson-Ekman G, Dahlen SE, Scheynius A, Gronlund H, van Hage M, Gafvelin G: Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy 2008;63:518–526.
19.
Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wuthrich B, Bot A, Kundig TM: Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005;35:1591–1598.
20.
Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout A: J, 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-β. J Immunol 2008;180:5211–5221.
21.
Lee SE, Koh YI, Kim MK, Kim YR, Kim SY, Nam JH, Choi YD, Bae SJ, Ko YJ, Ryu HJ, Koh JT, Choy HE, Rhee JH: Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008;28:157–165.
22.
van Etten E, Mathieu C: Immunoregulation by 1,25-dihydroxyvitamin D3:basic concepts. J Steroid Biochem Mol Biol 2005;97:93–101.
23.
Veldman CM, Cantorna MT, DeLuca HF: Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334–338.
24.
Ureta G, Osorio F, Morales J, Rosemblatt M, Bono MR, Fierro JA: Generation of dendritic cells with regulatory properties. Transplant Proc 2007;39:633–637.
25.
Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA: 1-α,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001;145:351–357.
26.
Penna G, Adorini L: 1 α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405–2411.
27.
Adorini L, Giarratana N, Penna G: Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004;16:127–134.
28.
Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker LS, Lammas DA, Raza K, Sansom DM: 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009;183:5458–5467.
29.
Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A: In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603–616.
30.
Gronlund H, Bergman T, Sandstrom K, Alvelius G, Reininger R, Verdino P, Hauswirth A, Liderot K, Valent P, Spitzauer S, Keller W, Valenta R, van Hage-Hamsten M: Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003;278:40144–40151.
31.
Jean J, Turcotte C, Simard RE, Fliss I: Production and characterization of polyclonal antibodies against cholecalciferol (vitamin D3). J Immunol Methods 1999;223:155–163.
32.
Andersson TN, Ekman GJ, Gronlund H, Buentke E, Eriksson TL, Scheynius A, Van Hage-Hamsten M, Gafvelin G: A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. Immunology 2004;113:253–259.
33.
Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83–93.
34.
Saarne T, Neimert-Andersson T, Gronlund H, Jutel M, Gafvelin G, van Hage M: Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011;66:255–263.
35.
Berer A, Stockl J, Majdic O, Wagner T, Kollars M, Lechner K, Geissler K, Oehler L: 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 2000;28:575–583.
36.
Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W: Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010;184:2194–2203.
37.
Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, Valenta R, Wenghoefer M, Appel T, Gros E, Niederhagen B, Bieber T, Lund K, Novak N: Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-β1 and IL-10-producing properties. J Allergy Clin Immunol 2010;126:638–645, e631.
38.
O’Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, Rolland JM, Sandrini A: House dust mite sublingual immunotherapy: the role for transforming growth factor-β and functional regulatory T cells. Am J Respir Crit Care Med 2009;180:936–947.
39.
Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P, Ramirez R: TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin Immunol 2001;107:647–653.
40.
Gardner LM, O’Hehir RE, Rolland JM: High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-γ+ T cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol 2004;133:1–13.
41.
Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:1467–1472, 1472, e1461.
42.
Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004;4:313–318.
43.
Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D, Valenta R: B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999;13:1277–1290.
44.
Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577–585.
45.
Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, Henin D, Benhamou M, Pretolani M, Blank U, Monteiro RC: Identification of FcαRI as an inhibitory receptor that controls inflammation: dual role of FcRγ ITAM. Immunity 2005;22:31–42.
46.
Tomassini M, Tsicopoulos A, Tai PC, Gruart V, Tonnel AB, Prin L, Capron A, Capron M: Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol 1991;88:365–375.
47.
Peebles RS, Jr, Liu MC, Adkinson NF, Jr, Lichtenstein LM, Hamilton RG: Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation. J Allergy Clin Immunol 1998;101:265–273.
48.
Shirinbak S, Taher YA, Maazi H, Gras R, van Esch BC, Henricks PA, Samsom JN, Verbeek JS, Lambrecht BN, van Oosterhout AJ, Nawijn MC: Suppression of th2-driven airway inflammation by allergen immunotherapy is independent of B cell and Ig responses in mice. J Immunol 2010;185:3857–3865.
49.
Monteiro RC, Van De Winkel JG: IgA Fc receptors. Annu Rev Immunol 2003;21:177–204.
50.
Takatsu K, Nakajima H: IL-5 and eosinophilia. Curr Opin Immunol 2008;20:288–294.
51.
Smolders J, Damoiseaux J, Menheere P, Hupperts R: Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194:7–17.
52.
Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O’Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM: Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006;116:146–155.
53.
Ranadive NS, Sehon AH: Antibodies to serotonin. Can J Biochem 1967;45:1701–1710.
54.
Holick MF: Vitamin D deficiency. N Engl J Med 2007;357:266–281.
55.
Van Etten E, Decallonne B, Verlinden L, Verstuyf A, Bouillon R, Mathieu C: Analogs of 1α,25-dihydroxyvitamin D3 as pluripotent immunomodulators. J Cell Biochem 2003;88:223–226.
56.
Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL: A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999;5:1339–1345.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.